Professor Catherine Hill is a clinical rheumatologist, epidemiologist and expert in evidence-based healthcare.She trained in clinical rheumatology and general medicine at TQEH/RAH, research fellowship and Masters of Science (Biostats & Epidemiology) at Boston University and MD (University of Adelaide).She leads the Rheumatology Research Group at the Basil Hetzel Institute with research expertise in population epidemiology, randomised clinical trials, qualitative research, biobanking and quality improvement. The Research Group has experts in epidemiology, statistics, biobanking, qualitative methods and evidence-based medicine. It is the South Australian hub of Australian Arthritis and Autoimmune Biobank (A3BC). She was awarded the 2022 Parr Prize for Rheumatology Research Excellence. It is awarded every three years for outstanding contribution by a ARA member to rheumatology research; judged on quality and impact of research.She is past President of Australian Rheumatology Association (2020-22); professional society of rheumatologists and rheumatology health professionals. She is Chair of the Education Committee of Asia Pacific League Against Rheumatism (APLAR).She has experience and expertise in health technology assessment having been Chair of South Australian Medicines Evaluation Panel (SAMEP; 2011-2023), member of Australian Committee for Prescription Medicine (TGA, 2004-2015) and member of Pharmaceutical Benefits Advisory Committee (2016-2023).She is a Board Member of the Australian and New Zealand Vasculitis Society as a founding Board Member. This is a collaborative organisation of physicians, scientists, and communities that focuses on research, education, and clinical practices in vasculitis.She is a Board Member of The Hospital Research Foundation (THRF). In addition, she chairs the Clinical Governance Committee of the THRF and sits on the THRG-Arthritis Board of Governors.As Chief Investigator of the North West Adelaide Health Study (NWAHS), she has instrumental in adding the musculoskeletal data collection to this study. Work from this study has been published as part of the Global Burden of Disease study published in the Lancet (2012), which identified musculoskeletal diseases one of the three most important diseases in terms of global disease burden. Prof Hill is part of a national OA trials collaborative (Monash University, University of Tasmania, University of Sydney, University of WA) with current and previous NHMRC funding of interventional clinical trials for knee and hand osteoarthritis. She has collaborations with CSIRO and University of SA for innovative trials of knee OA. Previous trials have been reported in JAMA and Ann Rheum Dis. Further to this work, she is part of the European League Against Rheumatism (EULAR) Hand OA classification criteria Working group.Giant Cell Arteritis is the most common vasculitis in the elderly that can lead to blindness and stroke. She established the South Australian Giant Cell Arteritis Registry in 2009 which has resulted in further knowledge about this condition in Australia for the first time and has resulted in both national and international collaborations; and the first Australian data regarding incidence and prevalence of this condition. She is involved in OMERACT (Outcome Measures in Rheumatology) which is an independent initiative of international health professionals interested in outcome measures in rheumatology since 2014. She co-chairs 4 working groups for OMERACT (PMR, glucocorticoid impact, hand OA, POLOS) and is also part of the Technical Advisory Group of OMERACT.